SELLAS Life Sciences (SLS) Change in Receivables (2013 - 2022)

SELLAS Life Sciences (SLS) reported Change in Receivables of $1.0 million for Q1 2022, up 31.93% on a QoQ basis from $758000.0 in Q2 2015.

SELLAS Life Sciences (SLS) has 4 years of Change in Receivables data on file, last reported at $1.0 million in Q1 2022.

  • Quarterly Change in Receivables changed N/A year-over-year to $1.0 million in Q1 2022, while the trailing twelve-month figure through Mar 2023 was $979000.0 (down 38.16% YoY) and the FY2014 annual result came in at -$1.6 million, down 144.64% from the prior year.
  • Change in Receivables advanced to $1.0 million in Q1 2022 per SLS's latest filing, from $758000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.0 million in Q1 2022 and bottomed at $1.0 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 208,524.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 110.42 Mn
10 SELLAS Life Sciences 1.61 Bn 1.61 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 1.00 Mn
Mar 31, 2022 1.00 Mn
Jun 30, 2015 758,000.00
Jun 30, 2015 758,000.00
Mar 31, 2015 -779,000.00
Mar 31, 2015 -779,000.00
Dec 31, 2014 604,000.00
Dec 31, 2014 604,000.00
Sep 30, 2014 -717,000.00
Sep 30, 2014 -717,000.00
Jun 30, 2014 686,000.00
Jun 30, 2014 686,000.00
Mar 31, 2014 -2.22 Mn
Mar 31, 2014 -2.22 Mn
Dec 31, 2013 2.14 Mn
Dec 31, 2013 2.14 Mn
Sep 30, 2013 1.54 Mn
Sep 30, 2013 1.54 Mn